TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07691606: A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)

Sponsor: Taiho Oncology, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$7,100,016

Rescue Site Savings

+$4,680,984

Unlock Full NCT07691606 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07691606 Rescue Dossier →